Kinase-Targeted Therapeutics: Development Pipelines, Challenges, and Opportunities
More Drug Discovery reports by CHI Insight Pharma Reports
R&D Trends Melanoma - Drug resistance provides an opportunity for drug developers by CHI Insight Pharma Reports
The melanoma market has seen a large increase in developer attention following breakthroughs in treatment over the past year. Datamonitor has identified 108 drugs in ...
Treatment Algorithms: Rectal Cancer – Inclusion of chemoradiation can influence treatment and prescribing trends by CHI Insight Pharma Reports
The rectal cancer pipeline has grown as pharmaceutical companies are attracted by the high incidence and success of other developers. Cytotoxics will remain an integral ...
Treatment Algorithms: Colon Cancer – Treatment dictated by stage, prior therapy, and reimbursement by CHI Insight Pharma Reports
Introduction The colon cancer pipeline has grown as pharmaceutical companies are attracted by the high incidence and success of other developers. Cytotoxics will remain an ...
R&D Trends: Non-Small Cell Lung Cancer - Mutation analyses continue driving treatment choices by CHI Insight Pharma ReportsSee all reports like this >>
The 220 drugs in the non-small cell lung cancer (NSCLC) pipeline, is dominated by targeted therapies across all stages. There are a growing number of ...
We can help you find what you need. Call us or write us:
Need help in your search?
Drug Discovery Reports